Conversely, since these and our previous data (Puccetti et al., 2017; 2019) demonstrate that loss of function of Zranb3 or Smarcal1 can negatively impact hematopoietic cell DNA replication, targeting of either may provide novel avenues of therapeutic intervention to treat aggressive hematopoietic malignancies and/or hyperproliferative hematologic conditions/syndromes. This evidence concerns the gene ZRANB3 and cancer.